醫療保健分銷市場- 按類型（藥品[OTC、學名藥、品牌藥]、生物製藥[疫苗、單克隆抗體] 和醫療器械分銷服務）、最終用途（醫院、零售藥房） - 全球預測(2024 - 2032 )

Healthcare Distribution Market - By Type (Pharmaceutical [OTC, Generic, Branded Drugs], Biopharmaceutical [Vaccines, Monoclonal Antibodies], & Medical Device Distribution Services), End-use (Hospital, Retail Pharmacies) - Global Forecast (2024 - 2032)

出版日期: 2024年06月04日 | 出版商:

Global Market Insights Inc. | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在倉庫管理系統 (WMS) 創新和對病人安全的高度關注的推動下，全球醫療保健分銷市場在 2024 年至 2032 年間將呈現 7.1% 的複合年成長率。先進的 WMS 技術可提高效率、準確性和法規遵循性，確保藥品的安全處理和分配。隨著病患安全變得越來越重要，對可靠、可追溯的分配系統的需求不斷增加，從而增強了供應鏈的信任和可靠性。這些創新和安全措施正在推動市場擴張，滿足醫療保健產業不斷變化的需求，並增強整體分銷實踐。

例如，2023 年 10 月，Tecsys 推出了用於醫療保健分銷的精英倉庫管理系統 (WMS)，旨在幫助公司遵守《藥品供應鏈安全法》(DSCSA) 法規。此類創新解決方案的推出反映了該行業對嚴格監管要求的回應以及對穩健、合規分銷實踐、推動市場成長和技術創新的需求。

醫療保健分銷行業根據類型、最終用途和地區進行分類。

由於對複雜和專業療法的需求不斷成長，到 2032 年，生物製藥產品分銷服務領域將大幅成長。生物製品和個人化醫療的興起需要先進的配送解決方案，以確保安全且有效率地處理溫度敏感產品。該細分市場受益於嚴格的監管要求以及精確物流以保持產品功效的需求。對冷鏈基礎設施和專業分銷網路的投資增加進一步支撐了生物製藥分銷服務在市場上的主導地位。

到 2032 年，由於這些藥房在醫療機構內管理和配藥方面發揮的關鍵作用，醫院藥房部門將獲得顯著成長。隨著醫院規模的擴大和醫療保健服務的增加，這些設施內對高效、可靠的藥品配送的需求不斷增加。醫院藥局需要專門的配送服務來處理各種藥物，包括複雜且高成本的治療藥物。它們在患者護理中的核心作用以及精確庫存管理的需求推動了它們在市場中的主導地位。

由於其完善的醫療保健基礎設施和先進的分銷網路，歐洲醫療保健分銷市場將在 2032 年之前保持適度的複合年成長率。該地區對監管合規、品質標準和高效供應鏈的高度重視支撐了其主導地位。此外，歐洲人口老化和對先進醫療產品不斷成長的需求推動了對強大分銷系統的需求。分銷實踐中技術與創新的整合進一步增強了歐洲的市場地位，使其成為全球醫療保健分銷產業前景的重要貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病發生率高、經濟負擔大
  - 有利的研發投資前景和隨後藥物上市的增加
  - 追蹤解決方案的成長
  - 越來越多採用學名藥
- 產業陷阱與挑戰
  - 營運成本高
  - 嚴格的法規遵循和變化
成長潛力分析
報銷場景
監管環境
- 美國
- 歐洲
- 亞太地區
技術景觀
- 核心技術
- 鄰近技術
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
醫藥產品分銷服務
- 非處方藥/維生素
- 學名藥
- 品牌/創新藥
生物醫藥產品經銷服務
- 單株抗體
- 疫苗
- 重組蛋白
- 血液和血液製品
- 其他產品
醫療器材分銷服務

第 6 章：市場估計與預測：按最終用途分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
其他最終用戶

第 7 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 8 章：公司簡介

Alliance Healthcare
AmerisourceBergen Corporation
Anda, Inc.
Cardinal Health, Inc.
Celesio AG
CuraScript SD
Henry Schein, Inc.
McKesson Corporation
Medline Industries, Inc.
Morris & Dickson Co., LLC
Owens & Minor, Inc.
Patterson Companies, Inc.
Pheonix Group
Sinopharm Group
Suzuken Co., Ltd.

簡介目錄

Product Code: 9732

Global Healthcare Distribution Market will demonstrate a 7.1% CAGR between 2024 and 2032, propelled by innovations in warehouse management systems (WMS) and a heightened focus on patient safety. Advanced WMS technologies improve efficiency, accuracy, and regulatory compliance, ensuring the secure handling and distribution of pharmaceuticals. As patient safety becomes increasingly critical, the demand for reliable, traceable distribution systems rises, fostering trust and reliability in the supply chain. These innovations and safety measures are propelling market expansion, meeting the evolving needs of the healthcare industry, and enhancing overall distribution practices.

For instance, in October 2023, Tecsys introduced its Elite Warehouse Management System (WMS) for Healthcare Distribution, designed to help companies comply with the Drug Supply Chain Security Act (DSCSA) regulations. The introduction of such innovative solutions reflects the industry's response to stringent regulatory requirements and the need for robust, compliant distribution practices, driving market growth and technological innovation.

The healthcare distribution industry is divided based on type, end-use, and region.

The biopharmaceutical product distribution services segment will see a considerable surge by 2032, attributed to the growing demand for complex and specialized therapies. The rise in biologics and personalized medicine requires advanced distribution solutions to ensure the safe and efficient handling of temperature-sensitive products. This segment benefits from stringent regulatory requirements and the need for precise logistics to maintain product efficacy. Increased investment in cold chain infrastructure and specialized distribution networks further supports the dominance of biopharmaceutical distribution services in the market.

The hospital pharmacies segment will garner notable gains by 2032, driven by the critical role these pharmacies play in managing and dispensing medications within healthcare settings. As hospitals expand and healthcare services increase, the demand for efficient, reliable pharmaceutical distribution within these facilities rises. Hospital pharmacies require specialized distribution services to handle a wide range of drugs, including complex and high-cost treatments. Their central role in patient care and the need for precise inventory management drive their dominant position in the market.

Europe healthcare distribution market will secure a moderate CAGR through 2032, owing to its well-established healthcare infrastructure and advanced distribution networks. The region's strong emphasis on regulatory compliance, quality standards, and efficient supply chains supports its dominance. Additionally, Europe's aging population and growing demand for advanced medical products drive the need for robust distribution systems. The integration of technology and innovation in distribution practices further enhances Europe's market position, making it a vital contributor to the global healthcare distribution industry outlook.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High incidence and large economic burden of chronic diseases
  - 3.2.1.2 Favorable R&D investment scenario and subsequent increase in drug launches
  - 3.2.1.3 Growth of track and trace solutions
  - 3.2.1.4 Growing adoption of generic drugs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High operational costs
  - 3.2.2.2 Stringent regulatory compliance and changes
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
- 3.5.3 Asia Pacific
3.6 Technological landscape
- 3.6.1 Core technologies
- 3.6.2 Adjacent technologies
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Pharmaceutical product distribution services
- 5.2.1 OTC drugs/vitamins
- 5.2.2 Generic drugs
- 5.2.3 Brand-name/innovator drugs
5.3 Biopharmaceutical product distribution services
- 5.3.1 Monoclonal antibodies
- 5.3.2 Vaccines
- 5.3.3 Recombinant proteins
- 5.3.4 Blood and blood products
- 5.3.5 Other products
5.4 Medical device distribution services

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospital pharmacies
6.3 Retail pharmacies
6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Rest of Middle East and Africa